HP 228
Code | Size | Price |
---|
TAR-T25507-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25507-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
HP 228 is a heptapeptide by inhibits the induction of nitric oxide synthase.
CAS:
109022-88-0
Molecular Weight:
942.08
Purity:
0.98
SMILES:
C([C@H](NC([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@H](CC2=CN=CN2)NC([C@@H](NC([C@H](CCCC)N)=O)CCC(N)=O)=O)=O)=O)CCCNC(=N)N)=O)C(NCC(N)=O)=O)C=3C=4C(NC3)=CC=CC4
References
Schi?th HB, Muceniece R, Wikberg JE. Characterization of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes. Neuropeptides. 1997 Dec;31(6):565-71. PubMed PMID: 9574823.
Weinger MB, Chaplan SR, Girten BE, Powell FL. The respiratory effects of the cytokine regulating agent HP 228 alone and in combination with morphine in human volunteers. Pharmacol Biochem Behav. 1998 Mar;59(3):759-66. PubMed PMID: 9512083.
Abou-Mohamed G, Papapetropoulos A, Ulrich D, Catravas JD, Tuttle RR, Caldwell RW. HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91. PubMed PMID: 7473142.
Girten B, McPherson S, Lee M, Grethe N, McDowell R, McPherson L, Tuttle RR. Effectiveness of a cytokine restraining agent (CRA (TM)) in attenuating disuse deconditioning induced by hindlimb unloading in rats. J Gravit Physiol. 1995;2(1):P121-2. PubMed PMID: 11538892.